Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-analysis of the Literature

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2014 Nov 8

PMID 25378766

Citations 13

Authors

Sheng-li Yang

Xiefan Fang

Zao-Zao Huang

Xiang-Jie Liu

Zhi-Fan Xiong

Ping Liu

Hong-Yi Yao

Chang-hai Li

Affiliations

Soon will be listed here.

Abstract

Objective: This review is to evaluate the diagnostic value of serum GPC3 for hepatocellular carcinoma (HCC) due to conflicting results reported.

Methods: NCBI PubMed and Embase were comprehensively searched for studies that have used serum GPC3 level as a diagnostic index for HCC. The quality of the included studies was assessed. Subgroup analyses were conducted to evaluate the sensitivity and specificity of GPC3 as a HCC marker. Statistical analysis was performed with the software STATA version 12.0.

Results: A total of 22 studies were included. The qualities of included studies were relatively poor. Among them, 18 studies have shown that serum GPC3 is a specific biomarker for HCC, and the pooled sensitivity and specificity of these studies were 69 and 93%, respectively. The other 4 studies have reported conflicting results, which were not caused by races, infection status of HBV and HCV, or assay reagents but due to one common experimental design of enrolling liver cirrhosis patients as control subjects.

Conclusions: This meta-analysis indicates that serum GPC3 is elevated in HCC patients compared with healthy individuals, but more studies are needed to evaluate its effectiveness to differentially diagnose HCC and liver cirrhosis.

Citing Articles

Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview.

Chinnappan R, Makhzoum T, Arai M, Hajja A, Abul Rub F, Alodhaibi I Diagnostics (Basel). 2024; 14(14).

PMID: 39061656 PMC: 11276200. DOI: 10.3390/diagnostics14141519.

WGCNA combined with machine learning to find potential biomarkers of liver cancer.

Lv J, Hou A, Zhang S, Dong J, Kuang H, Yang L Medicine (Baltimore). 2023; 102(50):e36536.

PMID: 38115320 PMC: 10727608. DOI: 10.1097/MD.0000000000036536.

Targeting GPC3 cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer.

Li D, Wang Y, Shi C, Fu S, Sun Y, Li C Ann Med. 2023; 55(1):2189295.

PMID: 37036308 PMC: 10088929. DOI: 10.1080/07853890.2023.2189295.

Evaluation for clinical and prognostic implications of glypican-3 and α-fetoprotein in hepatocellular carcinoma: a new subtype?.

Ye L, Li D, Chen Y, Yu X Transl Cancer Res. 2022; 9(5):3443-3452.

PMID: 35117710 PMC: 8798067. DOI: 10.21037/tcr-19-1803.

Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis.

Aydin Y, Koksal A, Thevenot P, Chava S, Heidari Z, Lin D J Hepatocell Carcinoma. 2021; 8:1579-1596.

PMID: 34917553 PMC: 8671108. DOI: 10.2147/JHC.S327339.

References

Masuzaki R, Karp S, Omata M . New serum markers of hepatocellular carcinoma. Semin Oncol. 2012; 39(4):434-9. DOI: 10.1053/j.seminoncol.2012.05.009. View

Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R . Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007; 111(5):316-22. DOI: 10.1002/cncr.22954. View

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao Y . Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401-16. PMC: 3899457. DOI: 10.2188/jea.je20100190. View

Chen M, Li G, Yan J, Lu X, Cui J, Ni Z . Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta. 2013; 423:105-11. DOI: 10.1016/j.cca.2013.04.026. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Zhang Q, Xiao Q, Lin Z, Ying X, Li Z, Lin J . Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem. 2010; 43(12):1003-8. DOI: 10.1016/j.clinbiochem.2010.04.074. View

Liu X, Hu Z, Liu X, Cao Y, Ding C, Hu C . Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Biochem. 2013; 47(3):196-200. DOI: 10.1016/j.clinbiochem.2013.12.007. View

Jia H, Ye Q, Qin L, Budhu A, Forgues M, Chen Y . Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007; 13(4):1133-9. DOI: 10.1158/1078-0432.CCR-06-1025. View

Honsova E, Lodererova A, Frankova S, Oliverius M, Trunecka P . Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma. Cas Lek Cesk. 2011; 150(1):37-40. View

10.

Grozdanov P, Yovchev M, Dabeva M . The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006; 86(12):1272-84. DOI: 10.1038/labinvest.3700479. View

11.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

12.

AbdelGawad I, Mossallam G, Radwan N, Elzawahry H, Elhifnawy N . Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?. Asian Pac J Cancer Prev. 2014; 14(12):7345-9. DOI: 10.7314/apjcp.2013.14.12.7345. View

13.

Yasuda E, Kumada T, Toyoda H, Kaneoka Y, Maeda A, Okuda S . Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res. 2010; 40(5):477-85. DOI: 10.1111/j.1872-034X.2010.00624.x. View

14.

Ozkan H, Erdal H, Kocak E, Tutkak H, Karaeren Z, Yakut M . Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal. 2011; 25(5):350-3. PMC: 6647704. DOI: 10.1002/jcla.20484. View

15.

Xu C, Yan Z, Zhou L, Wang Y . A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013; 139(8):1417-24. DOI: 10.1007/s00432-013-1458-5. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Li B, Liu H, Shang H, Li P, Li N, Ding H . Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. Afr Health Sci. 2013; 13(3):703-9. PMC: 3824453. DOI: 10.4314/ahs.v13i3.26. View

18.

Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S . Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res. 2004; 64(7):2418-23. DOI: 10.1158/0008-5472.can-03-2191. View

19.

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

20.

Wang W, Zhao L, Wang Y, Tao Q, Feitelson M, Zhao P . Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC. Cancer Biomark. 2012; 11(1):29-39. DOI: 10.3233/CBM-2012-0261. View